Pectoralis and Serratus Nerve Blocks for Mastectomy: a Prospective, Randomized, Single-blind Trial

NCT ID: NCT03966326

Last Updated: 2019-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-01

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pectoral nerve block provides a good alternative to epidural or paravertebral block with a lower risk for the patient and that is shown as an optimal anesthetic option with reduction in postoperative pain, anesthetic and opioid consumption. The main objective of this study is to evaluate the quality of the perioperative analgesia of the PECS block in patients electively escalated for the accomplishment of mastectomy under general anesthesia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The advent of ultrasound made possible greater safety and the creation of new peripheral blocks that aim to reduce the morbidity of the anesthetic technique on the cancer patient. Pectoral nerve block (PEC Block) is technically simple and easily reproducible. Inspired by the infraclavicular approach, it aims at the anesthesia of the pectoral, intercostobrachial, intercostal III-IV-V-VI nerves and the long thoracic nerve 8 being a safe, reproducible technique with little discomfort for the patients, with few complications and allowing a good control of acute pain.

The hypothesis is that the realization of pectoral nerve block provides a good alternative to epidural or paravertebral block with a lower risk for the patient and that is shown as an optimal anesthetic option with reduction in postoperative pain, anesthetic and opioid consumption. Main objective is the evaluation of postoperative pain through opioid consumption in the first 24 hours postoperatively.

Patients will undergo a prospective, randomized, single blind, placebo controlled study in which the examiners responsible for the postoperative evaluation will not know which of the two groups were randomly assigned: 40 patients in the Control and 40 patients in the PECS Group . Patients will be randomized through a list generated by www.randomizer.org into two groups.

Patients will receive standard monitoring, pre-anesthetic medication with midazolam 0.05 mg / kg EV. All patients will receive balanced general anesthesia with fentanyl 2 mcg / kg, lidocaine 2 mg / kg, propofol 1-2 mg / kg, cisatracurium 0.15 mg / kg or Rocuronium 0.6 mg / kg. The PECS II group will receive an injection of 20mL of 0.5% Ropivacaine between the serratus and the smaller pectoralis and 10mL of 0.5% ropivacaine between the pectoralis major and minor muscles with the aid of ultrasonography. Maintenance of anesthesia in the two groups: general anesthesia balanced with sevoflurane (with and fraction expired from 1 to 3%, to maintain BIS between 40 and 60). Prophylaxis for postoperative nausea and vomiting will be performed with slow intravenous administration following the anesthetic induction of Dexamethasone 4 mg, and at the end of the surgery slow intravenous administration of Ondansetron 4 mg. At the end of surgery, patients in both groups will receive Dipyrone 2 g and Parecoxib 40 mg. Patients will be evaluated in the postoperative times: T1: arrival at the PACU, T2: 3 hours postoperatively or discharge from the PACU), T3: 12 hours postoperative, T4: 24 hours postoperative.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Mastectomy (PECs) pectoral block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo group

Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and fentanil

Group Type PLACEBO_COMPARATOR

sevoflurane and fentanil

Intervention Type DRUG

Patients will receive standard general anesthesia

PECS II group

Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanil

Group Type ACTIVE_COMPARATOR

sevoflurane and fentanil plus PECS II block

Intervention Type DRUG

Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sevoflurane and fentanil

Patients will receive standard general anesthesia

Intervention Type DRUG

sevoflurane and fentanil plus PECS II block

Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Standard general anesthesia Standard general anesthesia plus PECS II block

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patients, aged 18 to 60 years, electively scheduled to perform mastectomy in the Base Hospital of the Federal District;
* Physical State 1, 2 or 3 the American Society of Anesthesiology (ASA);

Exclusion Criteria

* Patients with unstable angina
* Patient with poorly controlled asthma
* Substance abuse
* Heart failure, greater than first degree atrioventricular block
* Pregnant women
* Patients with allergy to dipyrone, morphine;
* Patients with chronic pain;
* Patients with severe hepatic disease;
* Patients with severe kidney disease;
* Patients with neurological diseases;
* Included patients in other clinical studies currently or in the past three months under general anesthesia;
* Patients who refuse to participate in the study;
* Any other condition that, in the opinion of the investigator, may pose a risk to the patient or interfere with the study objectives;
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital de Base

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fabricio Tavares Mendonca

Preceptor of anesthesiology medical residency

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fabricio T Mendonça, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital de Base do Distrito Federal

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital de Base do Distrito Federal

Brasília, Federal District, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fabricio T Mendonça, MD

Role: CONTACT

Phone: +5561981882640

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jamil Elias, MD

Role: primary

Viviane Rezende, MD

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

O'Scanaill P, Keane S, Wall V, Flood G, Buggy DJ. Single-shot pectoral plane (PECs I and PECs II) blocks versus continuous local anaesthetic infusion analgesia or both after non-ambulatory breast-cancer surgery: a prospective, randomised, double-blind trial. Br J Anaesth. 2018 Apr;120(4):846-853. doi: 10.1016/j.bja.2017.11.112. Epub 2018 Feb 14.

Reference Type BACKGROUND
PMID: 29576125 (View on PubMed)

Mendonca FT, Nascimento LFC, Veloso NM, Basto GCP. Long-term Efficacy of Pectoserratus Plane Block (PSPB) for Prevention of Post-mastectomy Pain Syndrome: Extended Follow-up From a Randomized Controlled Trial. Clin J Pain. 2023 Jul 1;39(7):334-339. doi: 10.1097/AJP.0000000000001118.

Reference Type DERIVED
PMID: 37083738 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PECS II block

Identifier Type: -

Identifier Source: org_study_id